The stock's rise snapped a four-day losing streak.

Fintel reports that on February 28, 2025, Stifel downgraded their outlook for Vertex (NasdaqGM:VERX) from Buy to Hold.

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex, Inc. (NASDAQ:VERX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat.com reports.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $41 from $56 and keeps a Market Perform rating on the ...

We recently compiled a list of the 10 Stocks Drop by Double Digits Mostly Due to Disappointing Earnings. In this article, we ...

Federal Territory of Kuala Lumpur, Malaysia, February 28, 2025 -- SurgeGraph, an AI writing tool focused on helping users ...

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

In Vermont, no day goes by without another news story about the lack of affordable, workforce, and senior housing.

About the company: SurgeGraph Vertex is an AI writing tool with a mission to help users grow their website traffic through ...

April users can now file in all 50 states; KSM launches IT services advisory; Expensify announces Expensify Travel; and other accounting tech news and updates.